Nuvation Bio Inc. — Director's Dealing 2021

Dec 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2021-03-31

Reporting Person: NODELMAN OLEG (Director)
Reporting Person: EcoR1 Capital, LLC (Affiliate of Director)
Reporting Person: EcoR1 Capital Fund, L.P. (Affiliate of Director)
Reporting Person: EcoR1 Capital Fund Qualified, L.P. (Affiliate of Director)
Reporting Person: EcoR1 Venture Opportunity Fund, LP (Affiliate of Director)
Reporting Person: Biotech Opportunity GP, LLC (Affiliate of Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-31	Class A Common Stock	P	151544	$10.45	Acquired	6735790	Indirect
2021-03-31	Class A Common Stock	S	151544	$10.45	Acquired	1145600	Indirect
2021-07-31	Class A Common Stock	P	56598	$8.64	Acquired	7198407	Indirect
2021-07-31	Class A Common Stock	S	56598	$8.64	Disposed	1147483	Indirect
2021-11-24	Class A Common Stock	P	163268	$7.6859	Acquired	7361675	Indirect
2021-11-24	Class A Common Stock	P	21758	$7.6859	Acquired	1169241	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	3165000	Indirect
Class A Common Stock	2200627	Indirect

Footnotes

F1: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds.

F2: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F3: Qualified Fund is the record holder of these securities.

F4: Capital Fund is the record holder of these securities.

F5: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, Capital Fund, Qualified Fund and Venture Fund. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC, but each Reporting Person disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.

F6: These securities are held of record by Venture Fund. Biotech indirectly beneficially owns these securities as the general partner of Venture Fund, and Mr. Nodelman indirectly beneficially owns these securities as the control person of Biotech and EcoR1.